Enlonstobart
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Enlonstobart
- enlonstobart
- Enlonstobart
- enlonstobart [INN]
- Enlonstobart [WHO-DD]
- Enlonstobart injection
- Enlonstobart Injection
- enlonstobart inn
- enlonstobart who dd
- gamma4 heavy chain Homo sapiens (1-440) [VH(Homo sapiens IGHV3-33*01 (92.8%) -(IGHD)-IGHJ4*01 (100%), CDR-IMGT [8.8.6] (26-33.51-58.97-102)) (1-113) -Homo sapiens IGHG4*01, nG4m(a)CH2 L92, G4v5 h P10 (CH1 (114-211), hinge 1-12 S10>P (221) (212-223), CH2 L92 (302) (224-333), CH3 (334-438), CHS (439-440)) (114-440)], (127-214')-disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01(97.9%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01(100%), Km3 A45.1 (153), V101 (191) (108'-214')], dimer (219-219'':222-222'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
- gamma4 heavy chain homo sapiens 1 440 vh homo sapiens ighv3 33 01 92 8 ighd ighj4 01 100 cdr imgt 8 8 6 26 33 51 58 97 102 1 113 homo sapiens ighg4 01 ng4m a ch2 l92 g4v5 h p10 ch1 114 211 hinge 1 12 s10 p 221 212 223 ch2 l92 302 224 333 ch3 334 438 chs 439 440 114 440 127 214 disulfide with kappa light chain homo sapiens 1 214 v kappa homo sapiens igkv3 11 01 97 9 igkj1 01 100 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 153 v101 191 108 214 dimer 219 219 222 222 bisdisulfide produced in chinese hamster ovary cho cells glycoform alfa
- Immunoglobulin G4 [221-proline], anti-(human programmed cell death protein 1) (human monoclonal SG001 γ4-chain), disulfide with human monoclonal SG001 κ-chain, dimer
- immunoglobulin g4 221 proline anti human programmed cell death protein 1 human monoclonal sg001 γ4 chain disulfide with human monoclonal sg001 κ chain dimer
- immunoglobulin g4 kappa anti homo sapiens pdcd1 programmed cell death 1 pd1 pd 1 cd279 homo sapiens monoclonal antibody
- Immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279)], Homo sapiens monoclonal antibody
- sg 001
- SG-001
- sg001
- Sg001
- SG001
- SG001 injection
- CAS registry numbers
- 2651230-53-2
- ChEMBL ID
- CHEMBL5315040
- FDA ingredient codes (UNII)
- H533QU433M
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- enlonstobart
- Type
- Antibody
- Drug name stem
- -bart
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- programmed cell death 1 (CD279)
- Gene symbol
- PDCD1
- Protein identifier
- Q15116
- Primary target
- Yes
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Mesothelioma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000588
- Subject identifier
- D008654
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002974
- Subject identifier
- D002583
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0000430
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002087
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004950
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005065
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005580
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006519
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0010150
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019086
- Highest recorded phase
- 1
- NCT03852823
- NCT04886700
- NCT05715840
- NCT05068141
- NCT05508659
- NCT06132217
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 290 $ 290''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVESGGGVVQPGRSLRLTCKASGLTFSSSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNNDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 127-214' $ 127''-214''' $ 134'-194' $ 134'''-194''' $ 140-196 $ 140''-196'' $ 219-219'' $ 222-222'' $ 254-314 $ 254''-314'' $ 360-418 $ 360''-418''
- Component
- Light chain
- Type
- Protein
- Sequence
- EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYTASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Related records
Trials (27)
- A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
- A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
- A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid Tumors
- A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
- A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
- A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors
- A Study of JMT101 in Patients With Metastatic Colorectal Cancer
- A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
- A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
- A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
- A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
- A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
- An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.
- Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
- Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
- Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
- JSKN003 Combined Treatment of HER2-positive Gastric Cancer
- Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
- Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
In development for (6)
- Breast cancer Phase 2
- Cervical cancer Phase 3
- Lymphoma Phase 1
- Mesothelioma Phase 1
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 1